Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC
- Conditions
- Squamous Cell Head and Neck Carcinoma
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Registration Number
- NCT03673735
Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Lingyu Luo
- Target Recruit Count
- 62
- Registration Number
- NCT03671538
Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Radiation: Intensity-modulated radiation therapyDrug: Paclitaxel liposomeDrug: CisplatinDrug: 5-Fluorouracil
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 215
- Registration Number
- NCT03668730
- Locations
- 🇨🇳
Hai Qiang Mai, Guangzhou, Guangdong, China
Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos
- Conditions
- Biliary Tract CancerEsophageal CancerColo-rectal CancerLiver CancerGastric CancerGall Bladder CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 120
- Registration Number
- NCT03668418
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 118
- Registration Number
- NCT03664024
- Locations
- 🇨🇦
CISSS de la Monteregie-Centre ( Site 0801), Greenfield Park, Quebec, Canada
🇭🇺Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0401), Szolnok, Hungary
🇮🇱Meir Medical Center ( Site 0501), Kfar-Saba, Israel
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 334
- Registration Number
- NCT03663205
- Locations
- 🇨🇳
Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Yunnan Cancer Hospital, Kunming, Yunnan, China
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
- Conditions
- Urinary Bladder NeoplasmsMuscle-Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 861
- Registration Number
- NCT03661320
- Locations
- 🇫🇮
Local Institution - 0146, Turku, Finland
🇩🇪Local Institution - 0013, Herne, Germany
🇧🇪Local Institution - 0060, Bruxelles, Belgium
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
- Conditions
- Unresectable CholangiocarcinomaMetastatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 167
- Registration Number
- NCT03656536
- Locations
- 🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
- Conditions
- Cancer of Pancreas
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT03649321
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
- Conditions
- HER2/Neu NegativeRecurrent Breast CarcinomaEstrogen Receptor NegativeMetastatic Breast CancerProgesterone Receptor NegativeTriple Negative Breast Cancer
- Interventions
- Biological: PembrolizumabDrug: Cisplatin
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2019-04-26
- Lead Sponsor
- University of Washington
- Registration Number
- NCT03644589
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.